title: [Treatment of acute lymphoblastic leukemia in low risk adults].
abstract: Forty five adult patients with low risk acute lymphoblastic leukemia were treated with prednisone, vincristine and adriamycin. 91 per cent (41 patients) obtained complete remission with a mean survival was of 39 months. The side effects of treatment were minimal and less patient had to delay his chemotherapy. This regimen of treatment is a good option for adults patients with low risk acute lymphoblastic leukemia, in consequence of: a) high value of complete remission and its duration. b) the mean survival obtained and the probability of cure. c) the absence of severe side effects and without necessity of support therapy or hospitalization.
authors.forename: M E
authors.initials: ME
authors.lastname: Rubio
authors.forename: A
authors.initials: A
authors.lastname: Avilés
authors.forename: F
authors.initials: F
authors.lastname: Tripp
authors.forename: E
authors.initials: E
authors.lastname: Murillo
authors.forename: J
authors.initials: J
authors.lastname: González-Llaven
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D011897:Random Allocation; D012074:Remission Induction; D012307:Risk Factors; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate
vernacular_title: Tratamiento de la leucemia aguda linfoblástica del adulto de riesgo bajo.